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Abstract: Cell scaffolds are often used in cell transplantation as they provide a solid structural
support to implanted cells and can be bioengineered to mimic the native extracellular matrix.
Gadolinium fluoride nanoparticles (Gd-NPs) as a contrast agent for Magnetic Resonance Imaging
(MRI) were incorporated into poly(lactide-co-glycolide)/chitosan scaffolds to obtain Imaging Labelled
Cell Scaffolds (ILCSs), having the shape of hollow spherical/ellipsoidal particles (200–600 µm diameter
and 50–80 µm shell thickness). While Gd-NPs incorporated into microparticles do not provide any
contrast enhancement in T1-weighted (T1w) MR images, ILCSs can release Gd-NPs in a controlled
manner, thus activating MRI contrast. ILCSs seeded with human mesenchymal stromal cells (hMSCs)
were xenografted subcutaneously into either immunocompromised and immunocompetent mice
without any immunosuppressant treatments, and the transplants were followed-up in vivo by MRI
for 18 days. Immunocompromised mice showed a progressive activation of MRI contrast within the
implants due to the release of Gd-NPs in the extracellular matrix. Instead, immunocompetent mice
showed poor activation of MRI contrast due to the encapsulation of ILCSs within fibrotic capsules
and to the scavenging of released Gd-NPs by phagocytic cells. In conclusion, the MRI follow-up of
cell xenografts can report the host cell response to the xenograft. However, it does not strictly report
on the viability of transplanted hMSCs.
Keywords: cell scaffold; graft transplantation; gadolinium; Magnetic Resonance Imaging; biomaterial;
human mesenchymal stromal cells (hMSC); immune response
1. Introduction
Despite the initial great promise of cell therapy, clinical trials have come up in many cases with
conflicting results and controversial clinical outcomes [1–3]. Known issues for the success of the
treatment are linked to the delivery of a stable and viable population of stem cells at the damaged
site, that is in turn strongly dependent on the administration route and dose. The abrupt change of
microenvironment conditions after grafting cells expanded in vitro into the host may further contribute
to cell loss. Finally, the host immune response is often indicated as a major cause of graft rejection.
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J. Funct. Biomater. 2019, 10, 28 2 of 15
Several strategies have been proposed to improve the delivery and retention of a stable and dense
population of therapeutic cells at the damaged site. Amongst these, the main strategy relies upon either
cell (micro)encapsulation and/or cell scaffolding [4–7]. Cell encapsulation makes use of biocompatible
hydrogels (e.g., alginate, hyaluronic acid, gelatin/collagen) to create a 3D environment in which cells
can be embedded. Cell encapsulation is often intended to shield therapeutic cells from the host hostile
environment by preventing the infiltration of immune cells. As an example, embedding of human
mesenchymal stromal cells (hMSCs) in a gelatin matrix prior to surgical grafting into the myocardium
in swine proved to be critical for increasing intra-myocardial retention of hMSCs [8]. Cell scaffolds are
made by synthetic biocompatible materials such as poly(lactide-co-glycolide), PLGA, bioengineered to
provide a solid structural support to implanted cells and to mimic the extracellular matrix, allowing
cells to proliferate and/or differentiate in the desired way [9]. Seeding neuronal stem cells on solid
supports (i.e., the cell scaffolds) prior to implantation has been shown to be essential to elicit tissue
regeneration in brain repair after stroke [6]. Solid scaffolds can be fabricated in different size and
forms (including solid foams, nanofibers, microspheres, or microtubules), depending on their specific
application [10]. Very interestingly, scaffolds can be designed to release bioactive molecules, such as
growth factors, DNA, or drugs, in a controlled manner to facilitate tissue regeneration [11].
The variability among individuals in regards to graft immune rejection still remains an issue [12].
Immune response can be directed against cells, against their solid supports or encapsulating materials,
triggered by the surgical act, or a combination of them. Foreign Body Response (FBR) has been
shown to cause fibrosis through activation of macrophages and dendritic cells as a reaction to alginate
capsules [13]. In the absence of methods enabling the real time-monitoring of the integrity of the cell
population and of their function, it is therefore very hard to assess whether inconsistent endpoint
clinical outcomes are due to graft rejection or poor intrinsic efficacy of the therapy. To bridge the
knowledge gap between cell therapy administration and endpoint health outcomes, there is a need
for non-invasive, clinically compliant methods enabling to follow-up longitudinally the cell state [14].
Magnetic Resonance Imaging (MRI) has gained a prominent role in the field of cell therapy because it
is minimally invasive, can image tissues at any depth in the body, and offer an acceptable compromise
between time/space resolution and sensitivity. Cell tracking by MRI allows one to follow the migration
and homing of cells after introduction within the host body [14,15]. An essential requirement to
track stem cells by MRI is the incorporation of an imaging probe (also called the contrast agent,
CA) into the cells of interest in order to distinguish them from their surroundings (direct labelling).
Superparamagnetic Iron Oxide (SPIO) nanoparticles have been extensively used to track cells by MRI.
Graft rejection can be assessed by following the homing of intravenously administered SPIO-labeled
macrophages in kidney transplantation [16] and xenotransplantation models [17]. Impairment of
SPIO-labelled pancreatic islet allografts due to rejection can be predicted in advance of functional
failure by MRI [18]. There are, however, drawbacks with the use of SPIO-labelled cells linked to the
long-term persistence of SPIO signal after the death of transplanted cells, leading to false results [19,20].
Furthermore, there are reports on the detrimental effects on stem cell multipotentiality linked to the
high payload of intracellular labels [21].
As an alternative to direct cell labelling, labelling of the extracellular matrix within cell capsules
was proposed, under the assumption that the cell state can be inferred by assessing the capacity of the
extracellular matrix (ECM) microenvironment to support cell survival [22,23]. Chan et al. reported
a pH-nanosensor-based MRI probe that could monitor microenvironment pH within cell-loaded
microcapsules in vivo and non-invasively. Onset of acidosis was shown to report about cell death within
grafted capsules [24]. In another study, cell infiltration and FBR response to alginate capsules could be
detected based on the Magnetization Transfer MR properties of the ECM microenvironment [13]. We
recently presented silica microspheres decorated with Gd-complexes as a redox-responsive MRI probe
to follow-up hypoxia within cell-embedding hydrogels [25]. In principle, a variety of microenvironment
features can be probed, providing that a suitable responsive system is available (for instance, liposomes
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grafted with MRI-labelled substrates for matrix metalloproteinases can be used to label the extracellular
microenvironment for probing matrix remodeling) [26].
In this study, we present novel biocompatible microparticles integrating a cell scaffolding
function for hMSCs with an imaging function to monitor immune response by MRI. Such Imaging
Labelled Cell Scaffolds (ILCSs) are designed to be seeded with cells, then embedded into a gelatin
matrix, and finally grafted into the host (Scheme 1). ILCSs are based on microparticles composed of
poly(lactide-co-glycolide) (PLGA) and chitosan (CHT). These microparticles incorporate gadolinium
fluoride nanoparticles (Gd-NPs) as the T1 MRI contrast agent [27]. As such, the incorporated Gd-NPs
are MRI silent, as they are shielded from any interaction with bulk water molecules. However, Gd-NPs
are slowly released into the extracellular milieu, where they become activated for T1-dependent
MRI contrast enhancement (Scheme 2). Due to their size (hydrodynamic diameter of ca. 12 nm;
inorganic core 2 nm) [27] and interactions with the macromolecular components of the extracellular
matrix, diffusion of Gd-NPs within the hydrogel is restricted, and local activation of MRI contrast is
expected. Foreign body response against scaffolded cells is expected to lead to fibrosis, encapsulation
of ILCSs, and scavenging of released Gd-NPs by phagocytic cells, preventing ultimately the activation
contrast enhancement.
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2. Results
2.1. Synthesis and Characterization of ILCSs
Microparticles were synthesized by the modified emulsion/solvent evaporation technique that is
commonly used for encapsulation of hydrophilic components, such as the suspension of Gd-NPs, into
the hydrophobic PLGA polymer. The main steps in the synthesis were: (i) Preparation of primary
emulsion (w/o) by emulsifying the aqueous suspension of Gd-NPs with PLGA dissolved in chloroform;
(ii) preparation of a second emulsion by transferring the primary emulsion into an excess volume of
water containing a mixture of CHT and poly(vinyl alcohol) (PVA) under vigorous stirring, and (iii)
final removal of the solvent accomplished by evaporation or extraction. The ILCSs synthetized by such
procedure have a payload of Gd-NPs of 18 ± 2 nmolGd per milligram of ILCS as far as evaluated by
means of Inductively Coupled Plasma-Mass Spectrometry (ICP-MS). Scanning Electron Microscopy
(SEM) images show a poly-dispersion of the particles, roughly splitting into a population of spherical
particles having a diameter less than 100 µm and a population of larger, hollow particles (Figure 1).
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Figure 1. SEM micrographs of ILCSs. ( rticles are hollow and quite poly-dispersed in size,
ranging from 200 µm to 60 µm. (b) Large l s on the surface reveal the i ner cavity of the
microspher s (c,d). Ten micron thick slices rticles show a sponge like structure within
the particle shell.
Although most of the larger particles have an lmost spherical shape with a diameter in the range
of 200 µm to 600 µm, others are ellipsoidal or cup-shaped. All large particles pres nt s v ral holes on
their surface that in some instances reveal the inner cavity. When cut into 10 µm thick slices, hollow
particles yield ring-shaped sections, whose thickness corresponds to that of the particle shell (typically
in the range 50–80 µm). The ring-shaped sections reveal a sponge-like structure, characterized by a
high density of spherical cavities likely left over by the evaporating solvent. Gadolinium analysis by
Energy Dispersive X-ray Spectroscopy (EDS) done on ring sections shows hot spots of gadolinium
atoms within the porous structures (Figure 2). Fluorine is co-localized with gadolinium, indicating
that Gd-NPs did not decompose during particle formation. Gd-NPs were detected within the polymer
matrix by Transmission Electron Microscopy (TEM, Figure S1).
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2.2. Release of Gd-NPs In Vitro
To assess Gd-NPs’ release from ILCSs, microparticles were embedded into 1% agar and agar
phantoms were incubated at RT for up to 24 days, while the MRI Signal Enhancement (SE) was
monitored at regular time intervals by means of T1 weighted (T1w) and T2 weighted (T2w) MRI.
ILCSs were visible by T2w-MRI as hypointense signal all along the follow-up time (Figure 3a). No
gadolinium-dependent signal enhancement was detected at day-0 in T1w MR images, and ILCSs could
be barely distinguished from the agar embedding them. However, ILCSs progressively developed
gadolinium dependent contrast, appearing as bright spots in T1w images. This indicated that an
appreciable fraction of Gd-NPs trapped within the PLGA polymer were released into the agar phase.
Figure 3b shows that the SE increases up to a plateau as a function of the incubation time.
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2.3. Biocompatibility
The biocompatibility of ILCSs has been assessed by incubating them with hMSCs for up to 20 days,
and by evaluating cell viability and morphology at regular time intervals. To this purpose, hMSCs
were cultured on a plate with ILCSs (either containing or not Gd-NPs). Confocal microscopy images
taken after one and two weeks of incubation showed that ILCSs were easily colonized by hMSCs, with
cells adhering to the microsphere surface or in between two adjacent microspheres (Figure 4; optical
images as well as SEM images of hMSCs adhering to the scaffolds are shown in Figures S2 and S3).
Cells were well-spread on particles and able to form large clusters, indicating a normal morphology.
The cell-seeded scaffolds were taken out the plate and placed into a new culture plate. Colonization of
the plate with hMSCs derived from ILCSs was achieved after one week, as expected for cells behaving
normally. No adverse effect on cell proliferation or morphology due to the ILCSs, either containing
Gd-NPs or not, were detected. hMSC viability in the presence of ILCSs (either containing or not
Gd-NPs) was comparable to the one of hMSC cultured in plate, as far as evaluated by the MTT assay
at different time points. Flow cytometry analysis after incubation with ILCSs revealed the positive
expression of the classical mesenchymal stem cell markers such as CD105, CD73, CD90, CD146 and
CD44 (Figure S4a). The percentage of markers expression was comparable to the one of hMSCs
cultured in the absence of ILCSs. hMSCs cultured for three weeks in adipogenic differentiation were
able to undergo adipogenic differentiation (Figure S4b) with positive stain for lipid droplets. Moreover,
cells maintained in osteogenic differentiation medium exhibited deposits of calcium, indicating an
osteogenic differentiation (Figure S4b). All these findings pointed out a very good biocompatibility of
ILCSs with no detrimental effects on multipotentiality.
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Figure 4. Confocal of hMSC se ed on ILCSs after (a) one and (b) two weeks of culture.
ILCSs are shown in red (fluor scent labelling wit rhodamine B); The cytoskeleton is visible in green
(phalloidin-FITC labelling); Cell nuclei are sho n i st staining).
2.4. MRI Follow-up In Vivo
Matrigel-embed ed, scaff l ll r i planted subcutaneously into either
im unoc mpet nt (FVB) i munocompromised (NSG) mice. Immunocompro is d mice
were chosen to mic an ideal case with minimal i mune response. I mun competent mice were
expect d to elicit im une r sponse, as they rec ived cell xenografts through a surgical act without any
immunosuppressant tre tment. Each mouse received two implants, one in the left flank contai ing
scaffolded hMSCs (+hMSC), and one in the contralateral side containing the scaffold only (−hMSC).
MR images showing the +hMSC implant of an immunocompromised mouse acquired at day-0 (i.e.,
the day after surgery) and at Day 12 p.i. are shown in Figure 5. The cell loaded ILCSs appeared as
hypointense spots over the homogenous gelatin background in T2w MR images all along the follow-up
period. The size of such spots suggested some extent of scaffold aggregation. In the T1w-MR image
at Day 0, both ILCSs and the gelatin background had a very low signal intensity, with ILCS being
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indistinguishable from the background. After 12 days, ILCSs lighted up to hyperintense signal,
indicating the release of Gd-NPs from the scaffold shell. The same behaviour was observed also
for the −hMSCs contralateral implant (Figure S5). The MRI follow-up protocol was applied to the
immunocompetent (FVB) mice as well. The baseline MR images (day-0) of +hMSC implants were very
similar to those of the immunocompromised mouse, with ILSCs appearing as hypointense spots in
T2w MR images and being undistinguishable from the background in T1w MR images. However,
no or poor activation of gadolinium dependent contrast was observed all throughout the follow-up
period (18 days). There was no activation of gadolinium dependent contrast in the –hMSC implants as
well. Figure 6 shows the time course of activation of gadolinium-dependent MR contrast enhancement
for all implants considered (n = 8). Immunocompromised mice showed activation of T1 contrast in all
their implants (n = 4), while poor activation was observed for immunocompetent mice (n = 4).
J. Funct. Biomater. 2019, 10, x FOR PEER REVIEW 7 of 15 
 
signal, indicating the release of Gd-NPs from the scaffold shell. The same behaviour was observed 
also for the −hMSCs contralateral implant (Figure S5). The MRI follow-up protocol was applied to 
the immunocompetent (FVB) mice as well. The baseline MR images (day-0) of +hMSC implants were 
very similar to those of the immunocompromised mouse, with ILSCs appearing as hypointense spots 
in T2w MR images and being undistinguishable from the background in T1w MR images. However, 
no or poor activation of gadolinium dependent contrast was observed all throughout the follow-up 
period (18 days). There was no activation of gadolinium dependent contrast in the –hMSC implants 
as well. Figure 6 shows the time course of activation of gadolinium-dependent MR contrast 
enhancement for all implants considered (n = 8). Immunocompromised mice showed activation of T1 
contrast in all their implants (n = 4), while poor activation was observed for immunocompetent mice 
(n = 4). 
 
Figure 5. Expansions of MR images around the +hMSCs grafts (ROI marked in yellow) in an 
immunocompromised NSG mouse (a–d) and an immunocompetent FVB mouse (e–h). ILCSs seeded 
with hMSCs appear as hypointense spots on the uniform matrigel background in T2w-MR images, 
both for the NSG (a,c) and the WT mouse (e,g). In the T1w-MR image at Day 0, ILCSs can be hardly 
distinguished from the background both in the NSG (b) and the FVB (f) mouse. After 12 days, ILCSs 
are clearly bright in the T1w-MR image of the NSG mouse (d) but not in that of the FVB mouse (h). 
 
Figure 6. Time course of T1w MRI signal enhancement (SE) of ILCSs grafted subcutaneously in mice. 
The SE increases with time in immunocompromised (NSG) mice (solid squares), while it does not 
change appreciably in immunocompetent (FVB) mice. The SE was averaged over n = 4 implants for 
NSG mice and n = 4 implants for FVB mice (error bars are ±SD; t-test: * p < 0.05, *** p < 0.005). 
Figure 5. Expansions of MR images ar h SCs grafts (ROI marked in yellow) in an
immunoc mpromised NSG mouse (a–d) and an i tent FVB mouse (e–h). ILCSs se ed
with hMSCs appear as hypointense spots on the if tri el background in T2w-MR images,
both for the NSG (a,c) and the WT mouse (e,g). I t e 1 - R image at Day 0, ILCSs can be hardly
distinguished from the background both in the S (b) and the FVB (f) mouse. After 12 days, ILCSs
are clearly bright in the T1w-MR image of the NSG mouse (d) but not in that of the FVB mouse (h).
J. Funct. io ater. 2019, 10, x F   I  7 of 15 
 
si l, i ic ti  t  r l s  f - s fr  t  sc ff l  s ll.  s  i r s s r  
ls  f r t  s c tr l t r l i l t ( i r  ).  I f ll -  r t c l s li  t  
t  i c t t ( ) ic  s ll.  s li   i s ( - ) f  i l ts r  
r  si il r t  t s  f t  i c r is  s , it  I s ri  s i t s  s ts 
i  2   i s  i  isti is l  fr  t  c r  i  1   i s. r, 
 r r cti ti  f li i  t c tr st s s r  ll t r t t  f ll -  
ri  (  s). r  s  cti ti  f li i  t c tr st i  t   i l ts 
s ll. i r   s s t  ti  c rs  f cti ti  f li i - t  c tr st 
c t f r ll i l ts c si r  (   ). I c r is  ic  s  cti ti  f 1 
c tr st i  ll t ir i l ts (   ), il  r cti ti  s s r  f r i c t t ic  
(   ). 
 
i re 5. x a si s f  i a e  r  t e + s rafts ( I ar e  i  ell ) i  a  
i c r ise   se (a– ) a  a  i c ete t  se (e– ). I s see e  
it  s a ear as i te se s ts  t e i r  atri el ac r  i  2 -  i a es, 
t  f r t e  (a,c) a  t e  se (e, ). I   1 -  i a e at a  0, I s ca  e ar l  
isti is e  fr  t e ac r  t  i  t e      (f) se. fter 12 a s, I s 
are clearl  ri t i  t e 1 -  i a e f t e   ( ) t t i  t at f t e  se ( ). 
 
i re 6. i e c rse f 1  I si al e a ce e t ( ) f I s rafte  s c ta e sl  i  ice. 
e  i creases it  ti e i  i c r ise  ( ) ice (s li  s ares), ile it es t 
c a e a recia l  i  i c ete t ( ) ice. e  as a era e  er  = 4 i la ts f r 
 ice a   = 4 i la ts f r  ice (err r ars are ± ; t-test: * p < 0.05, *** p < 0.005). 
Figure 6. Time course of T1w MRI signal enhancement (SE) of ILCSs grafted subcutaneously in mice.
The SE increases with time in immunocompromised (NSG) mice (solid squares), while it does not
change appreciably in immunocompetent (FVB) mice. The SE was averaged over n = 4 implants for
NSG mice and n = 4 implants for FVB mice (error bars are ±SD; t-test: * p < 0.05, *** p < 0.005).
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2.5. Histology of Excised Cell Grafts
On Day 20, mice were sacrificed and the implants were recovered (a representative one is
shown in Figure S6) and histological analysis was performed by hematoxylin/eosin (H&E), Masson
trichrome, and Sirius red stains to assess the extent of host cell infiltration and matrigel reorganization.
Immunocompromised NSG mice showed very low infiltration of host cells within the matrigel matrix,
no vascular organization or collagen remodelling of the matrigel, as seen by the uniform stain of the
matrigel (Figure 7). Spare foamy cells were detected within the matrigel. There were no significant
differences in the histologic appearance between implants seeded (+hMSC) or not (−hMSC) with cells
(the latter is shown in Figure S7). A large number of hMSC transplanted into mouse were found to
be still adhering to the scaffold by immunostaining specific for the HLA antigen (Figure 7e,f). These
cells appeared spread, forming clusters and dividing, indicating a healthy condition. In addition,
some clusters of hMSCs were also found within the matrigel phase, indicating that hMSCs have also
migrated and proliferated (Figure 7d).
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In the immunocompetent FVB mice, the hydrogel matrix was highly infiltrated with cells as shown
by the H&E, Masson trichrome, and Sirius red stains of both +hMSC and –hMSC implants. Most of the
microspheres were delimited by an intense fibrotic reaction, and extensive vascular reorganization of
the matrigel took place. Several foamy cells were detected, indicating phagocytosis of the degraded
scaffolds. Notwithstanding severe infiltration of host cells, the HLA immunostaining revealed that
hMSCs with normal morphology were still present in the implant, mostly residing in the hydrogel
matrix rather than on the scaffold surface (Figure 7j,k). Apparently, migration of transplanted cells
from the scaffold to the hydrogel bulk took place.
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3. Discussion
The delivery of therapeutic cells in association with biomaterials provides the outstanding
opportunity to add microenvironment-responsive imaging labels in a form interspersed with therapeutic
cells. While the incorporation of MRI probes into the extracellular space within hydrogel-based
microcapsules has several examples [22], the labelling of cell scaffolds received comparatively much
less attention [28,29]. To the best of our knowledge, this is the first study with cell scaffolds labelled
with MRI probes endowed with responsivity to the cell extracellular microenvironment. The system
we designed is intended to detect the infiltration of host cells in the gelatin matrix, embedding
scaffolded cells. It is worth emphasizing that the matrigel we used for cell embedding does not
provide immune-isolation in itself. As opposite, it is permeable to host cells and allows for matrix
remodelling. It was chosen for a better delivery of cell grafts, and to model cell infiltration within the
graft. If immunoisolation of embedded cells is sought for a specific implementation of cell therapy,
microencapsulation through suitable hydrogelling polymers, such as alginate, must be used instead.
We performed an initial evaluation of our follow-up system on either immunocompromised or
immunocompetent mice, under the hypothesis of no immune response in the former animals, and
occurrence of immune response in the latter. Endpoint ex vivo histology confirmed such an hypothesis,
as we observed poor or no infiltration of host cells with immunocompromised mice, and extensive
infiltration and matrix remodelling in immunocompetent mice. The extent of cell infiltration was
not affected by the presence of hMSCs, as no significant histologic differences between +hMSCs and
–hMSCs cell grafts were found. The endpoint histologic observation was nicely paralleled by MRI
observations. We detected a progressive appearance of MRI contrast in grafts devoid of host infiltrate.
On the other hand, poor MRI contrast appeared in the presence of appreciable infiltration, likely
due to the encapsulation of ILCSs within fibrotic capsules and to the scavenging of released Gd-NPs
by phagocytic cells. Therefore, the imaging response well correlates with cell infiltration within the
matrigel phase.
The relationship between the MRI response and cell survival is less clear. Surviving hMSCs
were detected ex vivo both in infiltrated and non-infiltrated grafts. The survival of xenogeneic cells
up to 20-days post transplantation even under the circumstance of strong infiltration can be due to
the type of cells we have used in our work. A number of studies have shown that hMSCs have
unique immunoregulatory functions [30–32] that make them promising for long-term cell therapy.
Human MSCs were xenografted in rat and swine without immunosuppressant treatment and gene
expression was imaged by PET [8]. Human MSCs were xenotransplanted in intervertebral discs in
a xenogeneic porcine model and shown to survive for months [33]. Mouse MSCs showed unique
immunologic tolerance, allowing their engraftment into a xenogeneic environment [34]. As +hMSC
implants were indistinguishable from –hMSC implants, it can be speculated that immune response is
directed against the microparticles rather than against xenogeneic cells. This would be in line with
other reports, showing a mild FBR directed against alginate microcapsules [13]. In summary, while
MR image response is clearly related to host cell infiltration, it cannot be unambiguously related to the
death of transplanted cells. Further quantitative assessment of survival of hMSCs cells within in vivo
xenograft is needed to shed light on this matter.
4. Materials and Methods
4.1. Synthesis and Characterization of ILCSs
Citrate-coated GdF3 nanoparticles (Gd-NPs) were prepared as described previously [27].
ILCSs incorporating Gd-NPs were prepared by a modified double emulsion-solvent evaporation
technique [35]. Firstly, one gram of commercial PLGA granules (Durect Lactel Absorbable Polymers,
Cupertino, CA, USA; lactide-to-glycolide ratio 50:50; Mw 40,000–50,000 g/mol) was dissolved into
5 mL of chloroform for 24 h (solution A). Solution B was prepared by dissolving 100 mg of PVA
(Sigma-Aldrich, St. Louis, MO, USA, Mowiol™ 4–88, Mw ~31,000) in 100 mL of dd-H2O on a magnetic
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stirrer at 1200 rpm and 90 ◦C for 30 min. After that, solution B was left to cool down at room temperature.
Meanwhile, for the preparation of solution C, 50 mg of CHT (Sigma-Aldrich, medium molecular
weight, 75–85% de-acetylated) were dissolved in 50 mL of 1% (v/v) acetic acid by stirring for 30 min at
500 rpm. The pH of solution C was adjusted to pH 5 with NaOH, and solution C was added to solution
B under stirring at 1200 rpm for 60 min (solution D). The primary emulsion was prepared by dropwise
addition of 1 mL Gd-NPs suspension (20 mM gadolinium concentration) into solution A, under 5 min
homogenization using a high-energy homogenizer (Ultra-Turrax T25, IKA, Königswinter, Germany).
This PLGA/Gd-NPs emulsion was added dropwise to the mixture of CHT and PVA (i.e., solution D),
under stirring at 1200 rpm, which led to the formation of a double emulsion. The final emulsion was
left under stirring for 20 h to promote chloroform evaporation. The microparticles formed within the
final stage were recovered by filtration and washed 3 times with dd-H2O on filter paper and finally
allowed to dry in air at RT. Control microparticles (i.e., gadolinium-free) were prepared by the same
protocol but in the absence of Gd-NPs.
The microparticles were labelled with rhodamine B to allow for optical imaging. One hundred mg
of microspheres were placed in a tube with 2.5 mL of HEPES buffer (3.8 mM HEPES, 150 mM NaCl, pH
7.4). 1.2 mg of rhodamine B isothiocyanate (Sigma-Aldrich) were dissolved in 1 mL of HEPES buffer.
500 µL of the fluorescent tag solution were added to the microspheres and the reaction mixture kept
under shaking at room temperature for 24 h. 3.5 mL of HEPES buffer were added to the solution and
the microparticles were washed 3 times for 15 min. The micropaticles were dialyzed for 48 h against
HEPES. The recovered microspheres were finally recovered by filtration and allowed to dry in air.
The gadolinium content of microparticles was determined by means Inductively Coupled
Plasma-Mass Spectrometry, ICP-MS (Spectro Genesis ICP-OES, Spectro Analytical Instruments, Kleve,
Germany) equipped with a crossflow nebulizer. Plasma was generated by argon with a power of
1400 W. Flow conditions, coolant flow 12.00 L/min, auxiliary flow 0.60 L/min, and nebulizer flow
1.00 L/min. Determinations were done in triplicate. Prior to the analysis, the sample was mineralized
in HNO3/HCl 1:3 v/v (aqua regia; 5 mL) and HF (2 mL) at 100 ◦C for 24 h.
Scanning Electron Microscopy (SEM) micrographs were taken with a Leo 1550 SEM instrument
(Zeiss, Oberkochen, Germany). Samples were mounted on aluminum stubs using a double-sided
adhesive carbontape and sputtered with Au/Pd with a plasma current of 30 mA for 30 s. The thickness
of Au/Pd layer was approximately 10 nm.
Optical images were acquired using an Olympus BX41 optical microscope (Olympus Corporation,
Tokyo, Japan).
4.2. Cell Culture and Biocompatibility Assessment
Human MSCs were purchased from Lonza, cultured and characterized, as previously described [36–38].
hMSCs were maintained in the presence of cysteine free Mesenchymal Stem Cells Basal Medium
(MSCBM, Lonza, Basel, Switzerland). All cell preparations at different passages of culture expressed
the typical MSC markers, CD105, CD73, CD44, CD90, and CD146 and not hematopoietic markers like
CD45, CD14 and CD34, as evaluated by flow cytometry assay [39] (see Table S1 for the complete list of
antibodies used in this study).
4.2.1. hMSC Culture on ILCSs
The culture of hMSCs on ILCSs was performed by incubating six mg of ILCSs (containing approx.
110 nmol of gadolinium under the form of Gd-NPs) with 1.5 × 104 hMSCs in the normal culture
medium. hMSCs and ILCSs were maintained in incubator at 37 ◦C for 4 days; after that, further
1.5 × 104 hMSCs were added to the flasks on the ILCSs and maintained in culture for up to 20 days.
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4.2.2. Biocompatibility Assessment
The biocompatibility of the microspheres, incubated with hMSCs, has been assessed for up to
20 days by evaluating cell viability, morphology, flow cytometry analysis, and in vitro osteogenic and
adipogenic differentiation.
MTT assay. For the evaluation of hMSCs vitality on ILCSs, the MTT (3-(4,5-dimethylthiazol-2-yl)
-2,5-diphenyltetrazolium bromide) assay was performed. Briefly, ILCSs after 7 days of culture were
re-suspended in 300 µL of PBS solution for efficient disaggregation. ILCS-derived cells were plated in
96-well plates in triplicates and analyzed according to the manufacturer’s instructions (Merck-Millipore,
Burlington, MA, USA).
Flow cytometry assay. hMSCs were detached from ILCSs with non-enzymatic cell dissociation
solution (Sigma, St. Louis, MO, USA), washed in PBS and then incubated for 30 min at 4 ◦C with the
appropriate fluorescein isothiocyanate (FITC) or phycoerythrin (PE) conjugate Abs or with the irrelevant
control in PBS containing 0.1 BSA (Sigma). The following antibodies, all PE- or FITC-conjugated, were
used, anti-CD146, -CD105, -CD90, CD73, CD44, alpha 5 integrin. Cells were analysed on a FACS (Becton
Dickinson, Franklin Lakes, NJ, USA). Ten thousand cells were analysed in each experimental point.
In Vitro Osteogenic and Adipogenic differentiation. For adipogenic differentiation, hMSCs were
recovered after incubation with ILCSs and incubated in appropriated adipogenic differentiation
medium (Lonza) [39]. The medium was changed two times per week for 3 weeks. The cells were
fixed with 10% formalin for 20 min at room temperature and stained with 0.5% Oil Red O (Sigma)
in methanol for 20 min at room temperature. For osteogenic differentiation, hMSCs were incubated
in osteogenic differentiation medium (Lonza) [39]. The media was changed two times per week
for 3 weeks. Then cells were fixed with 10% formalin for 20 min at room temperature and stained
with Alizarin Red, pH 4.1 (Sigma) for 20 min at room temperature. Images of undifferentiated or
differentiated cells were acquired at 20×magnification.
4.3. Confocal Imaging
Confocal microscopy was performed for the detection of the hMSCs on the microparticles by
means of a Zeiss LSM 5 Pascal Model Confocal Microscope (Carl Zeiss International, Oberkochen,
Germany). Ten ILCSs were recovered and stained with phalloidin-FITC, incubated for 1 h at room
temperature (Sigma-Aldrich), and with Hoechst 33,258 dye (Sigma-Aldrich) for nuclear staining.
Subsequently, ILCSs were seeded on microscope slides.
4.4. Release of Gd-NPs In Vitro
To evaluate the release of Gd-NPs in vitro, eight mg of microparticles were embedded into 1%
agar contained in 0.5 mL Eppendorf tube. The pH was kept at 7.4 (HEPES buffer, Sigma, St. Louis,
MO, USA). The volume of gelified agar was 150 µL. Twenty µL of HEPES buffer were placed on
top of the agar to keep the agar well hydrated. MR images were acquired with a Bruker Avance
microimaging MR scanner operating at 300 MHz (7 T). T1 weighted images were acquired with a
mic_msme (multislice-multiecho) pulse sequence, with TR 200 ms, TE 3.6 ms, FOV = 3.5 × 3.5 cm,
matrix 128 × 128, 15 slices 0.5 mm thick. T2 weighted images were acquired with a mic_RARE pulse
sequence, with TR 4000 ms, TE 4.4 ms, FOV = 3.5 × 3.5 cm, matrix 256 × 256, 15 slices 0.5 mm thick.
MRI images were acquired up to day 24.
4.5. Animal Studies
Animal studies were conducted in accordance with National Institute of Health Guidelines for
the Care and Use of Laboratory Animals. All procedures were approved by the Ethics Committee of
the University of Turin and the Italian Health Ministry (authorization number Prot. CC652.43). Mice
were kept in our institutional animal facility under controlled conditions of temperature, humidity
with access to food and water ad libitum.
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4.5.1. Cell Implants
Implants to be grafted in mice as described in Scheme 1 were prepared by seeding hMSCs on
scaffolds, as described in Section 4.2.1. The cell-loaded scaffolds (or control cell-free scaffolds) were
recovered and mixed with 150 µL of MatrigelTM (Becton Dickinson, Franklin Lakes, NJ, USA) and the
mixture kept ice cold. Such a mixture solution was surgically implanted subcutaneously on the back of
either immunocompromised NSG mice (n = 2), or immunocompetent FVB mice (n = 2). In detail, mice
were anesthetized with i.m. injection of 20 mg kg−1 tiletamine–zolazepam (Zoletil 100; Virbac, Milan,
Italy) mixed with 5 mg kg−1 xylazine (Rompun; Bayer, Milan, Italy) and, under sterile conditions, a
small skin incision was made on the back; the mixture was implanted using a large needle. Each mouse
received two subcutaneous implants, one implant contained scaffolded hMSCs (+hMSC, placed on the
left flank), and the other implant contained the cell-free scaffolds only (−hMSC, right flank). Follow-up
by MRI started at Day 0, i.e., the day after surgery. The animals were followed up for 18 days by MRI
and sacrificed at Day 20. The implants were excised and subjected to histology.
4.5.2. Magnetic Resonance Imaging
Prior to the acquisition of MR images, mice were anesthetized by i.m. administration of Zoletil
and Rompun (see above). MR images were acquired with a Bruker Avance microimaging MR scanner
(Bruker BioSpin, Rheinstetten, Germany) operating at 300 MHz (7 T). T1 weighted images were
acquired with a mic_msme pulse sequence, with TR 200 ms, TE 4.7 ms, FOV = 3.5 × 3.5 cm, matrix
256 × 256, 13 slices 1 mm thick. T2 weighted images were acquired with a mic_RARE pulse sequence,
with TR 2600 ms, TE 36 ms, FOV = 3.5 × 3.5 cm, matrix 384 × 384, 13 slices 1 mm thick. T1w and T2w
MRI images were acquired at day 0, 5, 7, 10, 12 and 18 post implantation. Image reconstruction was
performed with Paravision 5.1 and image analysis by ImageJ 1.47v.
T2w MR images at each time point were used to identify the regions of interest (ROI) within
matrigel that contained ILCSs. The Signal Enhancement (SE%) was then calculated on the corresponding
ROI on co-registered T1w MR images according to the formula:
SE% = 100 × (SIROI − SIref)/SIref (1)
where SIROI is the signal intensity measured in the ROI drawn around the ILCSs, and SIref is the signal
intensity measured on a reference sample. The reference sample was a vial containing phosphate
buffered saline, placed next to the imaged animal. As mice were imaged at different times, it was
not always possible to take and compare slices exactly at the same position. To have a consistent
quantitation of the time course of contrast enhancement, a set of 13 axial slices (each one mm thick)
were placed such to have a complete coverage of both +hMSC and –hMSC implants (Figure S8). T2w
and T1w MR images were co-registered. T2w images were used to define the ROI around ILCS, while
T1w weighted images were used to measure the gadolinium dependent SE due to released Gd-NPs.
The change of SE was averaged on the entire volume of the implant at every time point in the serial
images (with exclusion of slices suspected of partial volume artefacts; the smallest implant spanned
across four valid slices at least).
4.5.3. Histology
Cell implants were excised from mice at the end of the follow-up period (Day 20), and explants
were cut into 5 µm-thick sections. Sections were stained with hematoxylin and eosin (H&E) or
Masson trichrome, or Sirius red. Fluorescence confocal microscopy was performed for the detection
of the hMSCs in the implant. Sections were labelled with rabbit anti-HLA antibody (Cod, ab52922
Abcam, Cambridge Science Park, UK). Alexa Fluor anti-rabbit antibody (Molecular Probes, Leiden,
the Netherlands) was used as secondary antibody. Hoechst dye was added for nuclear staining.
Microscopy analysis was performed using an Aptome Zeiss (Carl Zeiss International, Oberkochen,
Germany).
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5. Conclusions
Microparticles endowed with controlled-release of Gd-NPs enable to integrate the cell scaffolding
function with an imaging function. Our initial in vivo study indicates that the MRI follow-up
of cell-loaded scaffolds can report on the host inflammatory response to the cell graft. However,
in its current form, this method does not provide quantitative information about the viability of
transplanted cells.
Supplementary Materials: The following are available online at http://www.mdpi.com/2079-4983/10/3/28/s1,
Table S1, and Figures S1–S8. Table S1. List of the antibodies used in this study. Figure S1. Transmission electron
micrographs of particle sections, showing electron dense Gd-NPs with diameter of 1–2 nm. Figure S2. Optical
images at the inverted microscope, showing hMSCs after 3 days seeding with ILCSs. The arrows show hMSCs on
the particle surface (A) or at the junction between particles (B–D). Figure S3. SEM micrographs of ILCSs seeded
with hMSCs (after 10 days culture) at (A) 500× and (B) 200×magnification. Cells have been fixed with formalin
for SEM. Cells appear mostly located at the junction between adjacent microparticles. Figure S4. Assessment of
the multipotentiality of hMSCs after incubation up to 20 days with ILCS. (A) Multipotentiality markers by flow
cytometry analysis; (B) Differentiation into adipocytes (middle, Oil Red staining) or osteocytes (right, Alizarin
Red staining). The left panel is the control. Figure S5. Expansions of MR images around the −hMSCs grafts
(contralateral to the implants shown in Figure 5, main text) in an immunocompromised NSG mouse (a–d) and
an immunocompetent FVB mouse (e–h). Similar to +hMSCs implants, activation of contrast enhancement in
T1w-MR images is observed in the immunocompromised mouse on going from day-0 (b) to day-12 (d). Poor
activation of contrast enhancement is observed for the immunocompetent mouse (f,h). Figure S6. Photograph of
the Matrigel-based hydrogel embedding cell-loaded ILCSs (pink spots) excised from an immunocompromised
mouse 20 days after implantation. Figure S7. Histology of -hMSC subcutaneous cell implants excised from a
representative immunocompromised NSG mouse (a–c) and immunocompetent FVB mouse (d–f). (a,d) H&E stains;
(b,e) Masson stains; (c,f) Sirius red stains. Arrows indicate microspheres delimited by an intense fibrotic reaction.
Arrow-heads are pointing the vascular organization of the matrigel. Double arrows are indicating macrophage
foamy cells. Scale bar: 50 µm for a,b,d,e; 25 µm for c,f. Figure S8. Schematics about the geometry of MRI slices
across ILCS implants to measure the signal enhancement (see main text, Section 4.5.2.).
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